Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21998302 | 0.85 | DDB1 (0.54) | DDB1CRBN | |
| SCHEMBL23842331 | 0.83 | DDB1 (0.39) | DDB1CRBN | |
| Trifluoroacetic Acid SCHEMBL27145106 | 0.80 | CRBN (0.47) | DDB1CRBN | |
| SCHEMBL31134459 | 0.79 | DDB1 (0.56) | DDB1CRBN | |
| SCHEMBL23572084 | 0.78 | DDB1 (0.43) | DDB1CRBN | |
| SCHEMBL22892879 | 0.78 | DDB1 (0.42) | DDB1CRBN | |
| SCHEMBL22526384 | 0.77 | CRBN (0.54) | DDB1CRBN | |
| SCHEMBL30169230 | 0.77 | CRBN (0.54) | DDB1CRBN | |
| SCHEMBL22849472 | 0.77 | KDM4E (0.36) | — | |
| SCHEMBL23832499 | 0.77 | CRBN (0.53) | DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | DDB1 1267/4885CRBN 187/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | DDB1 1267/4885CRBN 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.